Major depressive disorder (MDD) also known as clinical depression is a mental health disorder which affects mood, behavior as well as appetite and sleep. The exact cause of MDD is not known, however, several factors which can increase its risk is combination of genes and stress that affects brain chemistry and reduce the ability to maintain mood stability. Imbalanced hormone, alcohol or drug abuse, certain medical conditions such as cancer or hypothyroidism, and some adverse effects of medication such as steroids can also lead to MDD. Changing lifestyles such as work pressure, alcohol abuse, and others has resulted in increasing prevalence of MDD, which is expected to drive market growth over the forecast period. For instance, according to an article published in National Center for Biotechnology Information 2015, MDD is the most common psychiatric disorder in India and the lifetime prevalence of MDD is 10–25% for women, and 5–12% for men.
Increasing FDA approval for new drugs is expected to drive major depressive disorder (MDD) treatment market growth in the near future
Major depressive disorder treatment market is witnessing a dynamic change, where patents for drugs such as Cymbalta and Abilify has expired recently, and revenue generated from these drugs plummeted with the introduction of generics. Therefore, approval of new drugs such as Levomilnacipran, Brintellix, and Rexulti (brexpiprazole) is a primary driver for this market growth. FDA approved levomilnacipran — a new serotonin-norepinephrine reuptake inhibitor (SNRI) — for major depressive disorder (MDD) in adults in 2013. In the same year, Takeda Pharmaceutical Company Limited and H. Lundbeck A/S announced the FDA approval for Brintellix (vortioxetine) for the treatment of adults with major depressive disorder (MDD). Rexulti (brexpiprazole) tablets received approval from FDA as an add-on treatment to an antidepressant medication to treat adults with major depressive disorder (MDD) in July, 2015. These approvals are expected to provide more option to patients suffering from MDD, and this is expected to support the major depressive disorder treatment market growth.
Major Depressive Disorder (MDD) Treatment Market Taxonomy
The major depressive disorder (MDD) treatment market is segmented on the basis of product type and geography
On the basis of product type, major depressive disorder (MDD) treatment market is segmented into:
- Drug Type
- Selective Serotonin Reuptake Inhibitors (SSRIS)
- Lexapro (Escitalopram)
- Viibryd (Vilazodone)
- Dopamine Norepinephrine Reuptake Inhibitor
- Serotonin Norepinephrine Reuptake Inhibitor
- Cymbalta (Duloxetine)
- Effexor (Venlafaxine)
- Fetzima (Levomilnacipran)
- Savella (Milnacipran)
- Pristiq (Desvenlafaxine)
- Serotonin Modulators
- Norepinephrine-Serotonin Modulator
- Tricyclics and Tetracyclics
- Atypical Antidepressants
- Abilify (Aripiprazole)
- Seroquel XR (Quetiapine XR)
- Rexulti (Brexpiprazole)
- Stem Cell Therapy
North America is expected to be dominant in the market over the forecast period, owing to increasing prevalence of major depressive disorder
North America is expected to be dominant in major depressive disorder treatment market due to increasing prevalence of MDD in the U.S. For instance, according to National Institute of Mental Health In 2015, an estimated 16.1 million adults aged 18 or elder in the U.S. had at least one major depressive episode in the past year, representing 6.7% of all the U.S. adults. Europe is expected to be the second largest market for major depressive disorder treatment due to rapid approval of new therapies from regulatory bodies. For instance in 2015, Soterix Medical received CE Marking for its new tDCS depressive disorder therapy used for the treatment of MDD.
Key players operating in the major depressive disorder treatment market include Eli Lilly and Company, Allergan, Alkermes, Lundbeck, Johnson & Johnson, Pfizer, Inc., AstraZeneca plc, Merck & Co., GlaxoSmithKline plc. Sanofi S.A., and Takeda Pharmaceutical Company Limited.